Voltaren Triple Effect 1.16% Emulgel
A formulation designed for fast absorption6,7
After topical application, diclofenac penetrates through the skin and into the tissues beneath.8 It is retained in the muscle and other tissues that are often the source of pain.8,9
When it comes to topical NSAIDs, formulation can be more important than concentration.10 The Emulgel formulation possesses the advantages of both gels and emulsions, favouring rapid absorption, ease of application and good acceptability to patients.7,11,12
Voltaren Triple Effect penetrates through the skin to a depth of up to 1 cm, enabling targeted action against pain and inflammation.4,5
Effective relief of pain and reduction of inflammation1–3
In a randomised, double-blind, placebo-controlled study of patients with acute neck pain, Voltaren Triple Effect delivered significantly greater reduction in pain-on-movement and pain-at-rest – over three times that of placebo. Additionally, recovery time was about twice as fast as placebo.1*†
*Recovery time was defined as a clinically relevant decrease in pain plus an increase in neck function.†72 patients with acute neck pain received 2 g Voltaren Triple Effect (1.16%) Emulgel four times daily or placebo for 5 days.
The lowest number-needed-to-treat (NNT) vs other topical NSAIDs in acute musculoskeletal pain3,13
A Cochrane Review comparing topical NSAIDs and placebo showed favourable efficacy for Voltaren Emulgel*† vs other treatments. Of all topical NSAIDs tested for treatment of acute musculoskeletal pain, Voltaren Emulgel had the lowest NNT.3,13‡ with pain relief reported as similar to oral NSAIDs.
This means that for every single patient you treat with Voltaren Emulgel over other topical NSAIDs, you have a better chance of giving them the significant pain relief that helps get them back on their feet and enjoying life again.3
*1% and 2% Voltaren Emulgel formulations included in the review.†For treatment of strains, sprains or sports or overuse-type injuries.‡vs topical ibuprofen, ketoprofen, benzydamine, piroxicam and indomethacin.
Voltaren Emulgel with new application (Easy To Open Cap) which help the patient with fingers O.A to use the Voltaren Emulgel easy.
Voltaren Triple Effect has a reduced systemic side-effect risk15,16
The low systemic absorption of Voltaren Triple Effect means that it has a reduced risk of systemic side effects.8,15,16*
*There is an increased risk of mild dermatological side effects (e.g. skin irritation) with topical diclofenac, but this is non-serious and reversible.
First-line medication use
To improve pain, inflammation and recovery after sprains and strains, guidance from the National Institute for Health and Care Excellence (NICE) recommends using topical NSAIDs or paracetamol as initial analgesics for soft-tissue injuries.17
Patients should also be advised not to apply heat to the injury during the first 72 hours.17
Ben wants effective pain relief and fast recovery
Ben balances the demands of his full-time job with taking care of two young children.
He enjoys going to the gym or exercising outdoors and loves nothing more than playing with his children.
The last thing he needs is pain from a sprain or strain affecting his life.
Voltaren Triple Effect speeds recovery by relieving pain and reducing inflammation,1 so Ben can get back on with his life.
What can Voltaren Triple Effect Emulgel do for Peter?
Peter wants effective pain relief and fast recovery
Peter is a senior manager in a large multi-national company with a demanding commute. By the time he has driven 2 hours in each direction, he is usually experiencing pain in his left knee.
On days when his pain is troublesome, he needs pain relief that will allow him to get comfortable, so his evening is not disrupted.
Voltaren Triple Effect speeds recovery by relieving pain and reducing inflammation,1 so Peter can get back on with his life.
Recommend Voltaren Triple Effect to your patients for reduction of muscle pain and inflammation
Voltaren Triple Effect 1.16% Emulgel
For patients who are looking for relief from sprains and strains, using a topical formulation.
1 g of Voltaren Triple Effect 1.16% Emulgel contains 11.6 mg of diclofenac diethylamine, which corresponds to 10 mg of diclofenac sodium.
Also contains excipients (carbomer, macrogol cetostearyl ether, cocoyl caprylocaprate, diethylamine, isopropyl alcohol, propylene glycol, liquid paraffin, perfume cream 45 (containing benzyl benzoate) purified water).
Hypersensitivity to diclofenac, acetylsalicylic acid, and other non-steroidal anti-inflammatory agents, and to isopropanol or propylene glycol.
Voltaren Emulgel should be applied only to intact skin, and not to broken skin or open wounds. The preparation should not come into contact with the eyes or mucous membranes.
1st and 2nd trimesters: Animal studies have shown no risk to the fetus, but no controlled studies are available in pregnant women.
3rd trimester: Voltaren Emulgel should not be used owing to risk of premature closure of the ductus arteriosus and suppression of uterine contractility.
Undesirable side effects.
Occasional: allergic or non-allergic contact dermatitis (with symptoms and signs such as itching, reddening of the skin, oedema, papules, vesicles, bullae, or scaling).
OIsolated cases: generalised rash; hypersensitivity reactions (e.g. asthma attack, angioedema); photosensitivity reactions. The likelihood of systemic reactions occurring during topical treatment with diclofenac is small compared with the frequency of side effects seen during oral administration.
If Voltaren Emulgel is applied to large areas for prolonged periods, the possibility of systemic reactions cannot be completely ruled out. In such cases see product information for Voltaren.
The possibility of experiencing systemic adverse events (those associated with the use of systemic forms of diclofenac) should be considered if topical diclofenac is used at a higher dosage or for a longer period of time than recommended. Topical diclofenac should be applied only to intact, non-diseased skin, and not to skin wounds or open injuries. It should not be allowed to come into contact with the eyes or mucous membranes, and should not be ingested. Discontinue the treatment if a skin rash develops after applying the product.
Topical diclofenac can be used with non-occlusive bandages but should not be used with an airtight occlusive dressing.
Contains propylene glycol esters, which may cause mild, localised skin irritation in some people.
Contains benzyl benzoate which may cause mild, localised skin irritation in some people.
- Known hypersensitivity to diclofenac or to any of the excipients
- Patients in whom asthma, angioedema, urticaria, or acute rhinitis are precipitated by acetylsalicylic acid or other NSAIDs
- During the last trimester of pregnancy
For the full description of special warnings and precautions with Voltaren Triple Effect 1.16% Emulgel, please consult your local Summary of Product Characteristics.
The following convention has been utilised for the classification of undesirable effects: very common (≥ 1/10) common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000):
Infection and infestation
Immune system disorders
Angioedema, hypersensitivity (including urticaria)
Respiratory, thoracic and mediastinal disorders
Skin and subcutaneous tissue disorders Dermatitis (including contact dermatitis), rash, erythema, eczema, pruritus Common Dermatitis bullous Rare Photosensitivity reaction Very rare
For the full list of adverse reactions with Voltaren Triple Effect 1.16% Emulgel, please consult your local Summary of Product Characteristics.